A Study of Guselkumab and Interleukin-17 (IL-17) Inhibitor Therapies in Participants With Psoriatic Arthritis in Routine Clinical Practice

Inclusion Criteria:

Main study:

• Have a confirmed diagnosis of PsA as determined by a rheumatologist with referenceto Classification criteria for Psoriatic Arthritis (CASPAR)

• Start guselkumab or any approved interleukin-17 inhibitor (IL-17i) as a first,second, third, or fourth line of biologic disease-modifying antirheumatic drugs (bDMARD) therapy for the indication of PsA as part of standard clinical practice (according to local label, local regulations, and/or reimbursement requirements) atthe time of enrollment into the observational study or within a maximum of 2 monthsafter the initial baseline visit or after repeated baseline data collection

• Sign a participation agreement/Informed consent form (ICF) allowing data collectionand source data verification in accordance with local requirements

• Able to read, understand, and intend to comply with completion of all Electronicpatient-reported outcome (ePRO) instruments

• The treatment decision must be taken by the participating rheumatologist prior to,and independently of the participant's inclusion into the study, following clinicalpractice in accordance with local and overarching guidelines and local regulations

Substudy:

• Must sign the substudy ICF allowing data collection in accordance with localrequirements

• Is scheduled to receive guselkumab or IL-17i, per routine clinical practice, in themain study

• Currently using or is willing to use wearables and/or commercial applications totrack their disease within the course of their normal daily activities

Exclusion Criteria:

Main study:

• Start guselkumab or an IL-17i therapy as fifth or further line of biologic treatment

• Have already taken a specific IL-17i or IL-23i treatment and are planning onre-taking that specific treatment again

• Unwilling or unable to participate in long-term data collection

• Received an investigational drug (including investigational vaccines) or used aninvasive investigational medical device within 30 days before the start of the study (that is, signing of informed consent)

• Currently enrolled in any interventional study or any Janssen-sponsoredobservational clinical study (contemporary participation into observational studiesor registries not sponsored by Janssen is acceptable)

Substudy:

• Have an insufficient command of language to interact effectively with the smartphoneapplication, in the opinion of the investigator at each site

• Any condition for which, in the opinion of the investigator, participation would notbe in the best interest of the patient (example, compromise the well-being) or thatcould prevent, limit, or confound assessment

• Unwilling or unable to comply with substudy assessments